Acrivastine
| Structural formula | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||||||||
| General | ||||||||||||||||||||||
| Non-proprietary name | Acrivastine | |||||||||||||||||||||
| other names |
( E ) -3- [6 - [( E ) -1- (4-methylphenyl) -3-pyrrolidin-1-ylprop-1-enyl] pyridin-2-yl] prop-2-enoic acid ( IUPAC ) |
|||||||||||||||||||||
| Molecular formula | C 22 H 24 N 2 O 2 | |||||||||||||||||||||
| Brief description |
white solid |
|||||||||||||||||||||
| External identifiers / databases | ||||||||||||||||||||||
|
||||||||||||||||||||||
| Drug information | ||||||||||||||||||||||
| ATC code | ||||||||||||||||||||||
| Drug class | ||||||||||||||||||||||
| Mechanism of action |
Histamine H1 receptor antagonist |
|||||||||||||||||||||
| properties | ||||||||||||||||||||||
| Molar mass | 348.44 g / mol | |||||||||||||||||||||
| Melting point |
222 ° C |
|||||||||||||||||||||
| solubility |
soluble in DMSO |
|||||||||||||||||||||
| safety instructions | ||||||||||||||||||||||
|
||||||||||||||||||||||
| As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . | ||||||||||||||||||||||
Acrivastine is an active ingredient that is used to treat allergies . It is an antihistamine that works by blocking the histamine H1 receptor . Acrivastine is orally administered and the kidney excreted. The plasma half-life is 1.5 hours.
Trade names
- Benadryl Allergy Relief (UK), Semperx-D (USA)
No acrivastine-based drug is currently approved in Germany.
Individual evidence
- ↑ a b c d e aksci: [1]
- ↑ Data sheet Acrivastine, ≥98% (HPLC) from Sigma-Aldrich , accessed on November 1, 2016 ( PDF ).
- ^ Friedrich Kummer, Nikolaus Konietzko, Tullio C. Medici: Pharmacotherapy of bronchopulmonary diseases . Springer-Verlag, 2013, ISBN 978-3-7091-6761-8 , pp. 112 ( limited preview in Google Book search).
